MX2009003441A - Agonistas del receptor de eritropoyetina humana, composiciones, metodos y usos para prevenir o tratar condiciones relacionadas con la intolerancia a la glucosa. - Google Patents
Agonistas del receptor de eritropoyetina humana, composiciones, metodos y usos para prevenir o tratar condiciones relacionadas con la intolerancia a la glucosa.Info
- Publication number
- MX2009003441A MX2009003441A MX2009003441A MX2009003441A MX2009003441A MX 2009003441 A MX2009003441 A MX 2009003441A MX 2009003441 A MX2009003441 A MX 2009003441A MX 2009003441 A MX2009003441 A MX 2009003441A MX 2009003441 A MX2009003441 A MX 2009003441A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- preventing
- compositions
- glucose intolerance
- human epo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a por lo menos un agonista del receptor de EPO humana, métodos para prevenir o tratar la intolerancia a la glucosa y/o la anemia asociada con una enfermedad renal, incluyendo composiciones, métodos y dispositivos terapéuticos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82754106P | 2006-09-29 | 2006-09-29 | |
PCT/US2007/079964 WO2008042800A2 (en) | 2006-09-29 | 2007-09-28 | Human epo receptor agonists, compositions, methods and uses for preventing or treating glucose intolerance related conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009003441A true MX2009003441A (es) | 2009-10-16 |
Family
ID=39269124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009003441A MX2009003441A (es) | 2006-09-29 | 2007-09-28 | Agonistas del receptor de eritropoyetina humana, composiciones, metodos y usos para prevenir o tratar condiciones relacionadas con la intolerancia a la glucosa. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20100183592A1 (es) |
EP (1) | EP2109456A2 (es) |
JP (1) | JP2010511598A (es) |
KR (1) | KR20090077935A (es) |
CN (1) | CN101801403A (es) |
AU (1) | AU2007303527A1 (es) |
BR (1) | BRPI0717155A2 (es) |
CA (1) | CA2665037A1 (es) |
EA (1) | EA200970338A3 (es) |
IL (1) | IL197850A0 (es) |
MX (1) | MX2009003441A (es) |
NZ (1) | NZ575824A (es) |
SG (1) | SG175567A1 (es) |
UA (1) | UA98472C2 (es) |
WO (1) | WO2008042800A2 (es) |
ZA (1) | ZA200902916B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100034819A1 (en) * | 2006-03-31 | 2010-02-11 | Centocor Inc. | Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions on renal disease associated anemia |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
BR112014007029A2 (pt) * | 2011-09-23 | 2017-04-11 | Bluebird Bio Inc | métodos aperfeiçoados de terapia gênica |
JP6050289B2 (ja) * | 2013-07-11 | 2016-12-21 | Jcrファーマ株式会社 | 組換え蛋白質高発現細胞株の選択法 |
CN107998134A (zh) * | 2016-11-01 | 2018-05-08 | 江苏万邦生化医药股份有限公司 | 可博美在制备辅助治疗糖尿病足的药物制剂中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA05000202A (es) * | 2002-06-28 | 2005-09-30 | Johnson & Johnson | Cuerpos mimeicos ch1-deletados de epo de mimetica de mamifero. |
DE10234192B4 (de) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
ES2524916T3 (es) * | 2003-11-12 | 2014-12-15 | Sino-Med International Alliance, Inc. | Compuestos heterocíclicos de ácido borónico |
JP3930870B2 (ja) * | 2004-06-02 | 2007-06-13 | シャープ株式会社 | 電子写真用二成分現像剤 |
US20100034819A1 (en) * | 2006-03-31 | 2010-02-11 | Centocor Inc. | Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions on renal disease associated anemia |
-
2007
- 2007-09-28 CA CA002665037A patent/CA2665037A1/en not_active Abandoned
- 2007-09-28 AU AU2007303527A patent/AU2007303527A1/en not_active Abandoned
- 2007-09-28 US US12/442,723 patent/US20100183592A1/en not_active Abandoned
- 2007-09-28 EA EA200970338A patent/EA200970338A3/ru unknown
- 2007-09-28 MX MX2009003441A patent/MX2009003441A/es active IP Right Grant
- 2007-09-28 SG SG2011070521A patent/SG175567A1/en unknown
- 2007-09-28 WO PCT/US2007/079964 patent/WO2008042800A2/en active Application Filing
- 2007-09-28 UA UAA200904211A patent/UA98472C2/ru unknown
- 2007-09-28 BR BRPI0717155-2A patent/BRPI0717155A2/pt not_active IP Right Cessation
- 2007-09-28 JP JP2009530650A patent/JP2010511598A/ja active Pending
- 2007-09-28 CN CN200780043795A patent/CN101801403A/zh active Pending
- 2007-09-28 EP EP07843531A patent/EP2109456A2/en not_active Withdrawn
- 2007-09-28 KR KR1020097008742A patent/KR20090077935A/ko not_active Application Discontinuation
- 2007-09-28 NZ NZ575824A patent/NZ575824A/en not_active IP Right Cessation
-
2009
- 2009-03-26 IL IL197850A patent/IL197850A0/en unknown
- 2009-04-28 ZA ZA200902916A patent/ZA200902916B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
IL197850A0 (en) | 2011-08-01 |
CA2665037A1 (en) | 2008-04-10 |
EA200970338A3 (ru) | 2010-06-30 |
JP2010511598A (ja) | 2010-04-15 |
KR20090077935A (ko) | 2009-07-16 |
ZA200902916B (en) | 2010-10-27 |
WO2008042800A3 (en) | 2010-04-01 |
CN101801403A (zh) | 2010-08-11 |
EA200970338A2 (ru) | 2010-04-30 |
NZ575824A (en) | 2011-11-25 |
WO2008042800A2 (en) | 2008-04-10 |
SG175567A1 (en) | 2011-11-28 |
BRPI0717155A2 (pt) | 2013-10-15 |
EP2109456A2 (en) | 2009-10-21 |
AU2007303527A1 (en) | 2008-04-10 |
US20100183592A1 (en) | 2010-07-22 |
UA98472C2 (ru) | 2012-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE469895T1 (de) | Cgrp-rezeptorantagonisten | |
UA96308C2 (ru) | Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение | |
PL1984357T3 (pl) | Związki 2,4-pirymidynodiaminy do leczenia lub zapobiegania chorób autoimmunologicznych | |
WO2009012275A9 (en) | Pyridone gpr119 g protein-coupled receptor agonists | |
EP1993560A4 (en) | CANNABINOID RECEPTOR ANTAGONISTS / INVERSE AGONISTS TO TREAT OVERWEIGHT | |
WO2007111864A3 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
EP1962838A4 (en) | Farnesoid X RECEPTOR AGONISTS | |
WO2007136577A3 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
WO2007120689A3 (en) | Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual | |
GB2443287B (en) | Methods, compositions and formulations for the treatment of thyroid eye disease | |
IL195256A0 (en) | Compositions of r(+)and s(-)pramipexole and methods of using the same | |
TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
MX2009006339A (es) | Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide. | |
MX2008012400A (es) | Azolopirimidinas como inhibidores de actividad de cannabinoide 1. | |
MX2009009491A (es) | Compuestos y composiciones como moduladores de la actividad del gpr119. | |
MX2007012237A (es) | Amilina y agonistas de amilina para tratar enfermedades y trastornos siquiatricos. | |
WO2008007211A8 (en) | Substituted n-bicyclicalkyl bicyclic carboxyamide compounds | |
EP2023926A4 (en) | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL FOR TREATING HYPERPROLIFERATIVE AND ANGIOGENESIS RELATED DISORDERS | |
MX2009008222A (es) | Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama. | |
TW200800967A (en) | Benzimidazole thiophene compounds | |
MX2012002366A (es) | Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina. | |
MX2010006206A (es) | Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
MX2008015775A (es) | Compuestos y composiciones para tratamiento de cancer. | |
MX2009003441A (es) | Agonistas del receptor de eritropoyetina humana, composiciones, metodos y usos para prevenir o tratar condiciones relacionadas con la intolerancia a la glucosa. | |
EP2007602A4 (en) | HUMAN EPO MIMETICS IN HINGED CENTRAL REGION, COMPOSITIONS, METHODS AND USES IN THE PREVENTION OR TREATMENT OF GLUCOSE INTOLERANCE OR ANEMIA ASSOCIATED WITH NEPHROPATHY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |